ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Multimodal Cross-Attentive Graph-Based Framework for Predicting In Vivo Endocrine Disruptors.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Endocrine hazard assessment needs models that are accurate and mechanistically transparent. We present a multimodal cross-attentive graph framework that fuses molecular graphs with adverse-outcome-pathway (AOP)-anchored assay signals to predict organism-level outcomes in the organisation for economic co-operation and development (OECD) Hershberger and uterotrophic assays. In Tier-1, multitask graph neural networks (GNNs) learn estrogen and androgen receptor molecular-initiating and key events across 46 in vitro ToxCast/Tox21 assays. In Tier-2, a cross-attentive multimodal GNN integrates Tier-1 pathway signals with molecular graphs, yielding high predictive performance for both the in vivo Hershberger (AUROC = 0.97 ± 0.014) and uterotrophic (AUROC = 0.97 ± 0.008) assays. Retrospective analysis of literature compounds showed 88% concordance (Hershberger 15/18; uterotrophic 23/26). Bidirectional cross-attention highlights associations between molecular substructures and pathway-level assay nodes, while counterfactual perturbations rank assays and structural motifs most influential for each decision. The framework couple's high accuracy with assay-traceable explanations, supporting targeted testing within the integrated approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.